Broad consensus on the optimal sequence for the systemic treatment of metastatic breast cancer: results from a survey of Spanish medical oncologists

References

• Galceran J, Ameijide A, Carulla M, et al. Cancer incidence in Spain, 2015. Clin Transl Oncol. 2017;19:799–825.
   PubMed Web of Science ®Google Scholar
• Puig-Vives M, Sanchez MJ, Sanchez-Cantalejo J, et al. Distribution and prognosis of molecular breast cancer subtypes defined by immunohistochemical biomarkers in a Spanish population-based study. Gynecol Oncol. 2013;130:609–614.
   PubMed Web of Science ®Google Scholar
• Alvarez Lopez I, de la Haba Rodriguez J, Ruiz Simon A, et al. SEOM clinical guidelines for the treatment of metastatic breast cancer. Clin Transl Oncol. 2010;12:719–723.
   PubMed Web of Science ®Google Scholar
• Burstein HJ, Temin S, Anderson H, et al. Adjuvant endocrine therapy for women with hormone receptor-positive breast cancer: American society of clinical oncology clinical practice guideline focused update. JCO. 2014;32:2255–2269.
   PubMed Web of Science ®Google Scholar
• Cardoso F, Costa A, Norton L, et al. 1st International consensus guidelines for advanced breast cancer (ABC 1). Breast. 2012;21:242–252.
   PubMed Web of Science ®Google Scholar
• Cardoso F, Costa A, Norton L, et al. ESO-ESMO 2nd international consensus guidelines for advanced breast cancer (ABC2)dagger. Ann Oncol. 2014;25:1871–1888.
   PubMed Web of Science ®Google Scholar
• Gavila J, Lopez-Tarruella S, Saura C, et al. SEOM clinical guidelines in metastatic breast cancer 2015. Clin Transl Oncol. 2015;17:946–955.
   PubMed Web of Science ®Google Scholar
• GEICAM. Guía GEICAM de Práctica Clínica para el Diagnóstico y tratamiento del cáncer de mama metastásico Madrid2015 [updated 14/09/2016]. Available from: www.guiasalud.es/GPC/GPC_538_AF%20GUIA%20GEICAM_resumida.pdf
   Google Scholar
• Lin NU, Thomssen C, Cardoso F, et al. International guidelines for management of metastatic breast cancer (MBC) from the European School of Oncology (ESO)–MBC Task Force: surveillance, staging, and evaluation of patients with early-stage and metastatic breast cancer. Breast. 2013;22:203–210.
   PubMed Web of Science ®Google Scholar
• Zagouri F, Liakou P, Bartsch R, et al. Discrepancies between ESMO and NCCN breast cancer guidelines: an appraisal. Breast. 2015;24:513–523.
   PubMed Web of Science ®Google Scholar
• Mestres JA, iMolins AB, Martinez LC, et al. Defining the optimal sequence for the systemic treatment of metastatic breast cancer. Clin Transl Oncol. 2017;19:149–161.
   PubMed Web of Science ®Google Scholar
• Krop IE, Lin NU, Blackwell K, et al. Trastuzumab emtansine (T-DM1) versus lapatinib plus capecitabine in patients with HER2-positive metastatic breast cancer and central nervous system metastases: a retrospective, exploratory analysis in EMILIA. Ann Oncol. 2015;26:113–119.
   PubMed Web of Science ®Google Scholar
• Perou CM, Sorlie T, Eisen MB, et al. Molecular portraits of human breast tumours. Nature. 2000;406:747–752.
   PubMed Web of Science ®Google Scholar
• Gnant M, Mlineritsch B, Stoeger H, et al. Adjuvant endocrine therapy plus zoledronic acid in premenopausal women with early-stage breast cancer: 62-month follow-up from the ABCSG-12 randomised trial. Lancet Oncol. 2011;12:631–641.
   PubMed Web of Science ®Google Scholar
• Partridge AH, Pagani O, Abulkhair O, et al. First international consensus guidelines for breast cancer in young women (BCY1). Breast. 2014;23:209–220.
   PubMed Web of Science ®Google Scholar
• Sini V, Cinieri S, Conte P, et al. Endocrine therapy in post-menopausal women with metastatic breast cancer: from literature and guidelines to clinical practice. Crit Rev Oncol Hematol. 2016;100:57–68.
   PubMed Web of Science ®Google Scholar
• Hortobagyi GN, Stemmer SM, Burris HA, et al. Ribociclib as first-line therapy for HR-positive, advanced breast cancer. N Engl J Med. 2016;3;375:1738–1748.
   PubMed Web of Science ®Google Scholar
• Robertson JFR, Bondarenko IM, Trishkina E, et al. Fulvestrant 500 mg versus anastrozole 1 mg for hormone receptor-positive advanced breast cancer (FALCON): an international, randomised, double-blind, phase 3 trial. Lancet (London, England). 2016;388:2997–3005.
   PubMed Web of Science ®Google Scholar
• Verma S, Bartlett CH, Schnell P, et al. Palbociclib in combination with fulvestrant in women with hormone receptor-positive/HER2-negative advanced metastatic breast cancer: detailed safety analysis from a multicenter, randomized, placebo-controlled, phase III study (PALOMA-3). Oncologist. 2016;21:1165–1175.
   PubMed Web of Science ®Google Scholar
• Addeo R, Sgambato A, Cennamo G, et al. Low-dose metronomic oral administration of vinorelbine in the first-line treatment of elderly patients with metastatic breast cancer. Clin Breast Cancer. 2010;10:301–306.
   PubMed Web of Science ®Google Scholar
• Biganzoli L, Lichtman S, Michel JP, et al. Oral single-agent chemotherapy in older patients with solid tumours: a position paper from the International Society of Geriatric Oncology (SIOG). Eur J Cancer. 2015;51:2491–2500.
   PubMed Web of Science ®Google Scholar
• Gebbia V, Boussen H, Valerio MR. Oral metronomic cyclophosphamide with and without methotrexate as palliative treatment for patients with metastatic breast carcinoma. Anticancer Res. 2012;32:529–536.
   PubMed Web of Science ®Google Scholar
• Hernández-Blanquisett A, Touya D, Strasser-Weippl K, et al. Current and emerging therapies of HER2-positive metastatic breast cancer. Breast. 2016;29:170–177.
   PubMed Web of Science ®Google Scholar
• Isakoff SJ, Baselga J. Trastuzumab-DM1: building a chemotherapy-free road in the treatment of human epidermal growth factor receptor 2-positive breast cancer. JCO. 2011;29:351–354.
   PubMed Web of Science ®Google Scholar
• Swain SM, Baselga J, Kim SB, et al. Pertuzumab, trastuzumab, and docetaxel in HER2-positive metastatic breast cancer. N Engl J Med. 2015;372:724–734.
   PubMed Web of Science ®Google Scholar
• Verma S, Miles D, Gianni L, et al. Trastuzumab emtansine for HER2-positive advanced breast cancer. N Engl J Med. 2012;367:1783–1791.
   PubMed Web of Science ®Google Scholar
• Byrski TG, Huzarski T, Marczyk E, et al. Annual conference on hereditary cancers 2011 szczecin, poland. 17-18 november 2011. Hereditary Cancer Clin Pract. 2012;10(Suppl 3):A1–A23.
   PubMedGoogle Scholar
• Anders CK, Carey LA. Biology, metastatic patterns, and treatment of patients with triple-negative breast cancer. Clin Breast Cancer. 2009;9:S73–S81.
   PubMed Web of Science ®Google Scholar
• Kennecke H, Yerushalmi R, Woods R, et al. Metastatic behavior of breast cancer subtypes. JCO. 2010;28:3271–3277.
   PubMed Web of Science ®Google Scholar
• Zeichner SB, Terawaki H, Gogineni K. A review of systemic treatment in metastatic triple-negative breast cancer. Breast Cancer Basic Clin Res. 2016;10:25–36.
   PubMed Web of Science ®Google Scholar